Skip to main content
Top
Published in: Journal of Neuro-Oncology 2/2010

01-04-2010 | Case Report

Anti-CV2 associated cerebellar degeneration after complete response to chemoradiation of head and neck carcinoma

Authors: Emmanouel Saloustros, Ioannis Zaganas, Michail Mavridis, Lambros Vamvakas, Andreas Plaitakis, Vassilis Georgoulias, Dimitris Mavroudis

Published in: Journal of Neuro-Oncology | Issue 2/2010

Login to get access

Abstract

Paraneoplastic cerebellar degeneration is a rare neurological disorder that frequently precedes the detection of malignancy. Here, we report the case of a 60 year-old woman with locally advanced squamous cell carcinoma of the tongue who developed a subacute cerebellar syndrome associated with the presence of anti-CV2/CRMP5 antibodies in the cerebrospinal fluid, after achieving complete remission of the primary tumor and the involved cervical lymph nodes by chemoradiation. The patient’s symptoms on presentation were dizziness and gait unsteadiness. On examination she showed dysarthria, nystagmus and limb and gait ataxia. The diagnosis of paraneoplastic cerebellar syndrome was made on the basis of the clinical findings and immunological testing that revealed the presence of anti-CV2/CRMP5 antibodies in the patient’s cerebrospinal fluid. This syndrome, which is very rare in association with head and neck cancer, commonly precedes the detection of malignancy by a year or more and has been documented in only a few cases after completion of anticancer treatment.
Literature
1.
go back to reference Darnell R, Posner J (2003) Paraneoplastic syndromes involving the nervous system. N Engl J Med 349:1543–1554CrossRefPubMed Darnell R, Posner J (2003) Paraneoplastic syndromes involving the nervous system. N Engl J Med 349:1543–1554CrossRefPubMed
2.
go back to reference Shams’ili S, Grefkens J et al (2003) Paraneoplastic cerebellar degeneration associated with antineuronal antibodies: analysis of 50 patients. Brain 126:1409–1418CrossRefPubMed Shams’ili S, Grefkens J et al (2003) Paraneoplastic cerebellar degeneration associated with antineuronal antibodies: analysis of 50 patients. Brain 126:1409–1418CrossRefPubMed
3.
4.
go back to reference Greenberg HS (1984) Paraneoplastic cerebellar degeneration. A clinical and CT study. J Neurooncol 2:377–382CrossRefPubMed Greenberg HS (1984) Paraneoplastic cerebellar degeneration. A clinical and CT study. J Neurooncol 2:377–382CrossRefPubMed
5.
go back to reference Bonakis A, Papageorgiou SG, Mandellos D et al (2007) Acute onset paraneoplastic cerebellar degeneration. J Neurooncol 84:329–330CrossRefPubMed Bonakis A, Papageorgiou SG, Mandellos D et al (2007) Acute onset paraneoplastic cerebellar degeneration. J Neurooncol 84:329–330CrossRefPubMed
6.
go back to reference Frey A, Di Canzio J, Zurakowski D (1998) A statistically defined endpoint titer determination method for immunoassays. J Immunol Methods 1(22):35–41 Frey A, Di Canzio J, Zurakowski D (1998) A statistically defined endpoint titer determination method for immunoassays. J Immunol Methods 1(22):35–41
7.
go back to reference Carpentier AF, Voltz R, DesChamps T et al (1998) Absence of HuD gene mutations in paraneoplastic small cell lung cancer tissue. Neurology 50:1919PubMed Carpentier AF, Voltz R, DesChamps T et al (1998) Absence of HuD gene mutations in paraneoplastic small cell lung cancer tissue. Neurology 50:1919PubMed
8.
go back to reference Goldstein BH, Birk CL et al (2009) Ovarian cancer and late onset paraneoplastic cerebellar degeneration. Arch Gynecol Obstet 280(1):99–101CrossRefPubMed Goldstein BH, Birk CL et al (2009) Ovarian cancer and late onset paraneoplastic cerebellar degeneration. Arch Gynecol Obstet 280(1):99–101CrossRefPubMed
9.
go back to reference Honorat J, Byk T, Kusters I et al (1999) Ulip/CRMP proteins are recognized by autoantibodies in paraneoplastic neurological syndromes. Eur J Neurosci 11:4226–4232CrossRef Honorat J, Byk T, Kusters I et al (1999) Ulip/CRMP proteins are recognized by autoantibodies in paraneoplastic neurological syndromes. Eur J Neurosci 11:4226–4232CrossRef
10.
go back to reference Honnorat J, Cartalat-Carel S, Ricard D, Camdessanche JP, Carpentier AF, Rogemond V, Chapuis F, Aguera M, Decullier E, Duchemin AM, Graus F, Antoine JC (2009) Onco-neural antibodies and tumour type determine survival and neurological symptoms in paraneoplastic neurological syndromes with Hu or CV2/CRMP5 antibodies. J Neurol Neurosurg Psychiatry 80(4):412–416CrossRefPubMed Honnorat J, Cartalat-Carel S, Ricard D, Camdessanche JP, Carpentier AF, Rogemond V, Chapuis F, Aguera M, Decullier E, Duchemin AM, Graus F, Antoine JC (2009) Onco-neural antibodies and tumour type determine survival and neurological symptoms in paraneoplastic neurological syndromes with Hu or CV2/CRMP5 antibodies. J Neurol Neurosurg Psychiatry 80(4):412–416CrossRefPubMed
11.
go back to reference Arés-Luque A, García-Tuñón LA, Saiz A et al (2007) Isolated paraneoplastic optic neuropathy associated with small-cell lung cancer and anti-CV2 antibodies. J Neurol 254(8):1131–1132CrossRefPubMed Arés-Luque A, García-Tuñón LA, Saiz A et al (2007) Isolated paraneoplastic optic neuropathy associated with small-cell lung cancer and anti-CV2 antibodies. J Neurol 254(8):1131–1132CrossRefPubMed
12.
go back to reference Yu Z, Kryzer TJ, Griesmann GE et al (2001) CRMP-5 neuronal autoantibody: marker of lung cancer and thymoma-related autoimmunity. Ann Neurol 49(2):146–154CrossRefPubMed Yu Z, Kryzer TJ, Griesmann GE et al (2001) CRMP-5 neuronal autoantibody: marker of lung cancer and thymoma-related autoimmunity. Ann Neurol 49(2):146–154CrossRefPubMed
13.
go back to reference Graus F, Delattre JY, Antoine JC et al (2004) Recommended diagnostic criteria for paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry 75:1135–1140CrossRefPubMed Graus F, Delattre JY, Antoine JC et al (2004) Recommended diagnostic criteria for paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry 75:1135–1140CrossRefPubMed
14.
go back to reference Stich O, Rauer S (2007) Antigen-specific oligoclonal bands in cerebrospinal fluid and serum from patients with anti-amphiphysin- and anti-CV2/CRMP5 associated paraneoplastic neurological syndromes. Eur J Neurol 14:650–653CrossRefPubMed Stich O, Rauer S (2007) Antigen-specific oligoclonal bands in cerebrospinal fluid and serum from patients with anti-amphiphysin- and anti-CV2/CRMP5 associated paraneoplastic neurological syndromes. Eur J Neurol 14:650–653CrossRefPubMed
15.
go back to reference Buxtorf Hübscher E, Panizzon R (2001) Bazex syndrome. Dermatology 202:350–352CrossRef Buxtorf Hübscher E, Panizzon R (2001) Bazex syndrome. Dermatology 202:350–352CrossRef
16.
go back to reference Pillay PK, Estes ML (1993) Acute necrotizing myopathy in association with carcinoma of the tongue. Ann Acad Med Singap 22(Suppl 3):516–517 Pillay PK, Estes ML (1993) Acute necrotizing myopathy in association with carcinoma of the tongue. Ann Acad Med Singap 22(Suppl 3):516–517
17.
go back to reference Ferlito A, Elsheikh MN, Manni JJ, Rinaldo A (2007) Paraneoplastic syndromes in patients with primary head and neck cancer. Eur Arch Otorhinolaryngol 264:211–222CrossRefPubMed Ferlito A, Elsheikh MN, Manni JJ, Rinaldo A (2007) Paraneoplastic syndromes in patients with primary head and neck cancer. Eur Arch Otorhinolaryngol 264:211–222CrossRefPubMed
18.
19.
go back to reference Vedeler CA, Antoine JC, Giometto B et al (2006) Management of paraneoplastic neurological syndromes: report of an EFNS Task Force. Eur J Neurol 13:682–690CrossRefPubMed Vedeler CA, Antoine JC, Giometto B et al (2006) Management of paraneoplastic neurological syndromes: report of an EFNS Task Force. Eur J Neurol 13:682–690CrossRefPubMed
Metadata
Title
Anti-CV2 associated cerebellar degeneration after complete response to chemoradiation of head and neck carcinoma
Authors
Emmanouel Saloustros
Ioannis Zaganas
Michail Mavridis
Lambros Vamvakas
Andreas Plaitakis
Vassilis Georgoulias
Dimitris Mavroudis
Publication date
01-04-2010
Publisher
Springer US
Published in
Journal of Neuro-Oncology / Issue 2/2010
Print ISSN: 0167-594X
Electronic ISSN: 1573-7373
DOI
https://doi.org/10.1007/s11060-009-0022-2

Other articles of this Issue 2/2010

Journal of Neuro-Oncology 2/2010 Go to the issue